Lyka Labs Past Earnings Performance
Past criteria checks 0/6
Lyka Labs has been growing earnings at an average annual rate of 22.4%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 11.7% per year.
Key information
22.4%
Earnings growth rate
22.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.7% |
| Return on equity | -5.2% |
| Net Margin | -3.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Getting In Cheap On Lyka Labs Limited (NSE:LYKALABS) Is Unlikely
Apr 10
Subdued Growth No Barrier To Lyka Labs Limited's (NSE:LYKALABS) Price
Jan 05We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt
Nov 21These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively
Jun 08A Look At The Fair Value Of Lyka Labs Limited (NSE:LYKALABS)
Mar 15Unpleasant Surprises Could Be In Store For Lyka Labs Limited's (NSE:LYKALABS) Shares
Aug 25Is Lyka Labs (NSE:LYKALABS) A Risky Investment?
Jun 11These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well
Feb 21Statutory Profit Doesn't Reflect How Good Lyka Labs' (NSE:LYKALABS) Earnings Are
Nov 05These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well
Nov 03Revenue & Expenses BreakdownBeta
How Lyka Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,020 | -37 | 266 | 0 |
| 30 Sep 23 | 873 | -159 | 240 | 0 |
| 30 Jun 23 | 848 | -158 | 223 | 0 |
| 31 Mar 23 | 894 | -133 | 204 | 0 |
| 31 Dec 22 | 964 | -254 | 199 | 0 |
| 30 Sep 22 | 1,142 | -89 | 196 | 0 |
| 30 Jun 22 | 1,625 | 199 | 195 | 0 |
| 31 Mar 22 | 1,845 | 389 | 195 | 0 |
| 31 Dec 21 | 1,654 | 551 | 185 | 0 |
| 30 Sep 21 | 1,567 | 467 | 180 | 0 |
| 30 Jun 21 | 1,002 | 126 | 168 | 0 |
| 31 Mar 21 | 685 | -117 | 156 | 0 |
| 31 Dec 20 | 723 | -258 | 154 | 0 |
| 30 Sep 20 | 638 | -647 | 152 | 0 |
| 30 Jun 20 | 648 | -620 | 139 | 0 |
| 31 Mar 20 | 567 | -606 | 155 | 0 |
| 31 Dec 19 | 731 | -399 | 155 | 0 |
| 30 Sep 19 | 723 | -18 | 153 | 0 |
| 30 Jun 19 | 714 | -37 | 157 | 0 |
| 31 Mar 19 | 671 | -57 | 165 | 0 |
| 31 Mar 18 | 604 | -173 | 177 | 0 |
| 31 Mar 17 | 994 | -57 | 180 | 0 |
| 31 Dec 16 | 1,503 | -168 | 217 | 0 |
| 30 Sep 16 | 1,491 | -136 | 211 | 0 |
| 30 Jun 16 | 1,476 | -9 | 197 | 0 |
| 31 Mar 16 | 1,782 | 53 | 212 | 0 |
| 31 Dec 15 | 1,496 | 86 | 356 | 0 |
| 30 Sep 15 | 1,572 | 22 | 173 | 0 |
| 30 Jun 15 | 1,664 | -51 | 217 | 0 |
| 30 Jun 14 | 957 | -43 | 292 | 0 |
| 31 Dec 13 | 1,023 | -232 | 305 | 0 |
| 30 Sep 13 | 1,119 | -83 | 301 | 0 |
| 30 Jun 13 | 1,205 | -49 | 297 | 0 |
Quality Earnings: LYKALABS is currently unprofitable.
Growing Profit Margin: LYKALABS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LYKALABS is unprofitable, but has reduced losses over the past 5 years at a rate of 22.4% per year.
Accelerating Growth: Unable to compare LYKALABS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LYKALABS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: LYKALABS has a negative Return on Equity (-5.17%), as it is currently unprofitable.